173 related articles for article (PubMed ID: 36735547)
21. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
[TBL] [Abstract][Full Text] [Related]
22. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study.
Hu Y; Zhou Y; Zhang M; Zhao H; Wei G; Ge W; Cui Q; Mu Q; Chen G; Han L; Guo T; Cui J; Jiang X; Zheng X; Yu S; Li X; Zhang X; Chen M; Li X; Gao M; Wang K; Zu C; Zhang H; He X; Wang Y; Wang D; Ren J; Huang H
Cell Res; 2022 Nov; 32(11):995-1007. PubMed ID: 36151216
[TBL] [Abstract][Full Text] [Related]
23. Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.
Cao J; Wang G; Cheng H; Wei C; Qi K; Sang W; Zhenyu L; Shi M; Li H; Qiao J; Pan B; Zhao J; Wu Q; Zeng L; Niu M; Jing G; Zheng J; Xu K
Am J Hematol; 2018 Jul; 93(7):851-858. PubMed ID: 29633386
[TBL] [Abstract][Full Text] [Related]
24. CD4
Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
[TBL] [Abstract][Full Text] [Related]
25. [Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Ma RZ; He Y; Yang DL; Wei JL; Pang AM; Jiang EL; Wang JX; Han MZ; Zhang RL; Feng SZ
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):383-389. PubMed ID: 34218580
[No Abstract] [Full Text] [Related]
26. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
28. Base-Edited CAR7 T Cells for Relapsed T-Cell Acute Lymphoblastic Leukemia.
Chiesa R; Georgiadis C; Syed F; Zhan H; Etuk A; Gkazi SA; Preece R; Ottaviano G; Braybrook T; Chu J; Kubat A; Adams S; Thomas R; Gilmour K; O'Connor D; Vora A; Qasim W;
N Engl J Med; 2023 Sep; 389(10):899-910. PubMed ID: 37314354
[TBL] [Abstract][Full Text] [Related]
29. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
[TBL] [Abstract][Full Text] [Related]
30. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
31. Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma.
Dai HP; Cui W; Cui QY; Zhu WJ; Meng HM; Zhu MQ; Zhu XM; Yang L; Wu DP; Tang XW
Biomark Res; 2022 Feb; 10(1):6. PubMed ID: 35130959
[TBL] [Abstract][Full Text] [Related]
32. Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML).
Lu Y; Liu Y; Wen S; Kuang N; Zhang X; Li J; Wang F
J Transl Med; 2022 Dec; 20(1):600. PubMed ID: 36517851
[TBL] [Abstract][Full Text] [Related]
33. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies.
Freiwan A; Zoine JT; Crawford JC; Vaidya A; Schattgen SA; Myers JA; Patil SL; Khanlari M; Inaba H; Klco JM; Mullighan CG; Krenciute G; Chockley PJ; Naik S; Langfitt DM; Mamonkin M; Obeng EA; Thomas PG; Gottschalk S; Velasquez MP
Blood; 2022 Dec; 140(25):2684-2696. PubMed ID: 35914226
[TBL] [Abstract][Full Text] [Related]
34. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia.
Zhang C; He J; Liu L; Wang J; Wang S; Liu L; Ge J; Gao L; Gao L; Kong P; Liu Y; Liu J; Han Y; Zhang Y; Sun Z; Ye X; Yin W; Sersch M; Shen L; Cao WW; Zhang X
Blood Cancer J; 2022 Jun; 12(6):96. PubMed ID: 35750687
[TBL] [Abstract][Full Text] [Related]
35. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
36. CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
Li S; Wang X; Liu L; Liu J; Rao J; Yuan Z; Gao L; Li Y; Luo L; Li G; Li Z; Li S; He J; Zhang L; Chen L; Huang W; Yin P; Li C; Li X; Wang Y; Dong Y; Zhang D; Zang Q; Chen Y; Shen L; Li W; Cao W; Zhang X; Wang S
Leukemia; 2023 Nov; 37(11):2176-2186. PubMed ID: 37700087
[TBL] [Abstract][Full Text] [Related]
37. Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells.
Xie L; Gu R; Yang X; Qiu S; Xu Y; Mou J; Wang Y; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Hum Gene Ther; 2023 Dec; 34(23-24):1257-1272. PubMed ID: 37861302
[TBL] [Abstract][Full Text] [Related]
38. CD7 CAR T bridging to allo-HSCT in R/R T-ALL: A case report.
Fanqiao M; Chen X; Ren X; Li L; Wu T
Pediatr Transplant; 2024 May; 28(3):e14367. PubMed ID: 35860981
[TBL] [Abstract][Full Text] [Related]
39. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and therapeutic approaches for patients diagnosed with T-ALL/LBL exhibiting t(8;14)(q24;q11)/TCRA/D:MYC translocation.
Zhang X; Wang T; Zhang Y; Wang F; Chen J; Ni J; Sun R; Wei Z; Zhang G; Li W; Li J; Lu P
Leuk Lymphoma; 2023 Dec; 64(13):2133-2139. PubMed ID: 37674391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
